{
    "2018-03-05": [
        [
            {
                "time": "2018-05-01",
                "original_text": "Oral Semaglutide May Drive Solid Growth for NVO Going Forward",
                "features": {
                    "keywords": [
                        "Semaglutide",
                        "solid growth",
                        "NVO"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-01-01",
                "original_text": "Ozempic Is Expected to Boost GLP-1 Drug Class Trajectory in 2018",
                "features": {
                    "keywords": [
                        "Ozempic",
                        "GLP-1",
                        "boost"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-03-01",
                "original_text": "Victoza Continues to Lead in the GLP-1 Segment in 2018",
                "features": {
                    "keywords": [
                        "Victoza",
                        "GLP-1",
                        "lead"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-04-01",
                "original_text": "GLP-1 Drug Class May Continue to Drive Growth for Novo Nordisk",
                "features": {
                    "keywords": [
                        "GLP-1",
                        "growth",
                        "Novo Nordisk"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            }
        ]
    ]
}